Source:http://linkedlifedata.com/resource/pubmed/id/18200504
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2008-2-4
|
pubmed:abstractText |
T regulatory cells type 1 (Tr1 cells) are excellent candidates for cell therapy in multiple sclerosis (MS). The aim of our study was to assess the functional state of Tr1 cells and IL-10R signaling in patients with MS. Tr1 cells were induced in vitro by activation with anti-CD46 antibodies in controls and patients with MS. Cells were phenotyped by cytometry and suppression assays, and the expression of cytokines and transcription factors was evaluated by real-time PCR, ELISA, cytometry and Western blotting. We found that the activity of Tr1 cells and IL-10R signaling is impaired in MS patients since Tr1 cells isolated from MS patients produced less IL-10 than those obtained from controls. Indeed, the supernatants from Tr1 cells from controls did not suppress the proliferation of stimulated CD4(+) cells from patients with MS. Furthermore, the IL-10R signaling pathway was not fully active in CD4(+) cells from MS patients and these cells had higher baseline levels of SOCS3 transcripts than controls. Indeed, after in vitro IL-10 stimulation, the expression levels of the STAT1, STAT3 and IL-10RA genes were higher in MS patients than in controls. Moreover, Stat-3 phosphorylation was lower in controls than in patients after IL-10 stimulation. These results indicate that IL-10 regulatory function is impaired in patients with MS.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0014-2980
|
pubmed:author |
pubmed-author:BendandiMaurizioM,
pubmed-author:Fernandez-DiezBegoñaB,
pubmed-author:Garcia-MunozRicardoR,
pubmed-author:GonzalezZairaZ,
pubmed-author:InogesSusanaS,
pubmed-author:Lopez-Diaz de CerioAscensiónA,
pubmed-author:Martinez-ForeroIvanI,
pubmed-author:Martinez-PasamarSaraS,
pubmed-author:MeleroIgnacioI,
pubmed-author:MorenoBeatrizB,
pubmed-author:PalaciosRicardoR,
pubmed-author:SepulcreJorgeJ,
pubmed-author:VillosladaPabloP
|
pubmed:issnType |
Print
|
pubmed:volume |
38
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
576-86
|
pubmed:meshHeading |
pubmed-meshheading:18200504-Adult,
pubmed-meshheading:18200504-Cells, Cultured,
pubmed-meshheading:18200504-Down-Regulation,
pubmed-meshheading:18200504-Female,
pubmed-meshheading:18200504-Humans,
pubmed-meshheading:18200504-Immune Tolerance,
pubmed-meshheading:18200504-Interleukin-10,
pubmed-meshheading:18200504-Male,
pubmed-meshheading:18200504-Multiple Sclerosis,
pubmed-meshheading:18200504-Receptors, Interleukin-10,
pubmed-meshheading:18200504-Signal Transduction,
pubmed-meshheading:18200504-T-Lymphocytes, Regulatory
|
pubmed:year |
2008
|
pubmed:articleTitle |
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis.
|
pubmed:affiliation |
Department of Neurology, University of Navarra, Pamplona, Spain.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|